Analysts Set Tetraphase Pharmaceuticals, Inc. (TTPH) PT at $11.75

Shares of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) have been given an average recommendation of “Hold” by the seven analysts that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating on the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $10.65.

A number of brokerages have recently issued reports on TTPH. BidaskClub downgraded shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday. HC Wainwright began coverage on shares of Tetraphase Pharmaceuticals in a research report on Tuesday, July 11th. They issued a “buy” rating and a $15.00 price target on the stock. BMO Capital Markets restated a “buy” rating and issued a $12.00 price target on shares of Tetraphase Pharmaceuticals in a research report on Friday, May 5th. Needham & Company LLC restated a “hold” rating on shares of Tetraphase Pharmaceuticals in a research report on Thursday, July 27th. Finally, Stifel Nicolaus upgraded shares of Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their target price for the company from $8.00 to $15.00 in a research report on Wednesday, July 26th.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. UBS Group AG increased its position in Tetraphase Pharmaceuticals by 2.3% in the first quarter. UBS Group AG now owns 17,269 shares of the biopharmaceutical company’s stock worth $159,000 after buying an additional 387 shares during the last quarter. Schwab Charles Investment Management Inc. increased its position in Tetraphase Pharmaceuticals by 0.7% in the second quarter. Schwab Charles Investment Management Inc. now owns 129,681 shares of the biopharmaceutical company’s stock worth $925,000 after buying an additional 874 shares during the last quarter. Teza Capital Management LLC increased its position in Tetraphase Pharmaceuticals by 8.9% in the first quarter. Teza Capital Management LLC now owns 15,650 shares of the biopharmaceutical company’s stock worth $144,000 after buying an additional 1,281 shares during the last quarter. American International Group Inc. increased its position in Tetraphase Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 22,390 shares of the biopharmaceutical company’s stock worth $206,000 after buying an additional 1,486 shares during the last quarter. Finally, Citadel Advisors LLC increased its position in Tetraphase Pharmaceuticals by 18.6% in the first quarter. Citadel Advisors LLC now owns 15,924 shares of the biopharmaceutical company’s stock worth $146,000 after buying an additional 2,496 shares during the last quarter. Institutional investors own 35.76% of the company’s stock.

Shares of Tetraphase Pharmaceuticals (NASDAQ TTPH) opened at 5.35 on Thursday. The stock’s 50 day moving average price is $6.97 and its 200-day moving average price is $6.94. The company’s market cap is $273.13 million. Tetraphase Pharmaceuticals has a 12-month low of $3.11 and a 12-month high of $9.93.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.76) by $0.07. The firm had revenue of $1.59 million during the quarter, compared to analyst estimates of $1.54 million. Tetraphase Pharmaceuticals had a negative return on equity of 79.79% and a negative net margin of 2,092.20%. The firm’s revenue for the quarter was up 28.2% on a year-over-year basis. During the same quarter last year, the firm posted ($0.47) EPS. On average, equities research analysts forecast that Tetraphase Pharmaceuticals will post ($2.55) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Analysts Set Tetraphase Pharmaceuticals, Inc. (TTPH) PT at $11.75” was first published by Rincon Hill News and is the sole property of of Rincon Hill News. If you are accessing this piece on another website, it was illegally copied and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://rinconhillneighbors.org/2017/08/19/tetraphase-pharmaceuticals-inc-ttph-receives-11-75-average-pt-from-brokerages-updated-updated.html.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 

Latest News



Leave a Reply

 
© 2006-2017 Rincon Hill News.